Topic: drug-eluting stents
Medtronic showed that its Resolute Onyx drug-eluting stent showed success in patients at high risk for bleeding, who are often excluded from studies.
The drug-eluting balloon opens up the coronary arteries after they’ve reclogged without using a traditional drug coating.
On the back of a positive head-to-head trial, the FDA approved Boston Scientific’s drug-eluting stent for peripheral artery disease.
Reva netted a CE mark for the first drug-eluting bioresorbable scaffold in lower-leg peripheral artery disease, and the company’s first in the space.
Manufacturers including Abbott, Boston Scientific and Medtronic have argued that the ceiling makes their high-end products commercially unviable.
Here's Monday's medtech news of note.
VentureMed Group raised $15 million to support R&D, clinical trials and expand the sales team for its PAD treatment catheter.
The decision to can the program follows a succession of setbacks for Abbott’s rival stent that have dented the sector’s hopes of generating big sales.
Shockwave Medical, which markets a system that delivers ultrasound shockwaves to treat peripheral artery disease, has notched a CE mark for the treatment of coronary artery disease.
Medtronic has won FDA approval for its Resolute Onyx drug-eluting stent.